Lightpoint Medical and Telix Pharmaceuticals Sign Strategic...

Lightpoint Medical and Telix Pharmaceuticals Sign Strategic Partnership Agreement

Healthcare Tech Outlook | Tuesday, August 31, 2021

Graeme Smith, CEO, Lightpoint Medical

Lightpoint's SENSEI® probe for minimally invasive and robot-assisted surgery will be tested with Telix's molecularly targeted imaging agent TLX599-CDx.

FREMONT, CA: Lightpoint Medical, a leading medical device business that develops and markets miniaturized imaging and sensing equipment for minimally invasive and robot-assisted surgery, signs of a strategic collaboration agreement with Telix Pharmaceuticals Limited. The two businesses will investigate how Lightpoint and Telix technologies might be used together for real-time intra-operative cancer diagnosis under the terms of the partnership.

Lightpoint has created SENSEI®, a miniature surgical gamma probe for minimally invasive and robot-assisted cancer surgery approved for sale in the United States, the European Union, the United Kingdom, and Australia. SENSEI® can be utilized in conjunction with molecularly targeted imaging agents to directly diagnose cancer during surgery, assisting surgeons in removing cancer while conserving healthy, functional tissue.

Lightpoint and Telix will first assess the use of SENSEI® in conjunction with Telix's investigational prostate cancer SPECT imaging agent TLX599-CDx (99mTc-HYNIC-iPSMA) for the intraoperative identification of malignant pelvic lymph nodes. The collaboration aims to gain regulatory approval and commercialization for SENSEI® and TLX599-CDx for prostate cancer surgery.

In a press conference, Graeme Smith, CEO of Lightpoint, states that Lightpoint Medical has reached a significant milestone with its strategic cooperation arrangement with Telix. Combining the miniaturized surgical gamma probe, SENSEI®, and Telix's ground-breaking imaging agents is intended to create an exact technique to assist surgeons in detecting cancer that might not otherwise be found during surgery or confirm the absence of disease to assist surgeons in retaining healthy, functional tissue. The collaboration can improve surgical results for individuals suffering from various severe cancers, beginning with prostate cancer.

Dr. Christian Behrenbruch, CEO of Telix, adds that bringing molecular imaging into the operating room is an essential component of their urologic oncology portfolio strategy. The combination of Telix and Lightpoint technologies can potentially alter cancer treatment options. This collaboration strengthens Telix's pioneer in developing innovative surgical technologies based on highly targeted imaging techniques.

Weekly Brief